Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders
NCT ID: NCT00122629
Last Updated: 2005-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
405 participants
INTERVENTIONAL
2000-10-31
2003-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients with hepatitis C virus infection were eligible if they had failed to respond to a single previous 24 week cycle of interferon/ribavirin combination therapy. Non-response was defined as persistent HCV RNA in the serum during the last month of treatment.
This study tested the efficacy and safety of pegylated interferon alfa-2b with ribavirin and amantadine or a placebo for 48 weeks.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of this study is to determine if the addition of amantadine to PEG-IFN/ribavirin enhances SVR.
This study is a double blind, comparative, prospective multicenter, randomized study. Patients are recruited from 23 hepatology centers in France. The protocol was approved by the French ethical committee and all patients provided written informed consent. Eligible subjects are randomly assigned to the two treatment groups in equal proportions. The randomization process is generated by the Department of Biostatistics, Hospices Civils de Lyon, Lyon, France.
Main inclusion criteria are: elevated ALT, detectable HCV RNA, Metavir score over or equal to A1F1 and below or equal to F3. Patients received PEG-IFN 1.5µg/kg/week, ribavirin 800-1200mg/day and amantadine 200mg/day or placebo during 48 weeks.
The primary endpoint is a sustained virological response, defined as an undetectable HCV-RNA 24 weeks after treatment discontinuation (week 72). Secondary endpoints are the biochemical response at week 72 defined as ALT normalization; histological benefit; tolerance; and virological and biochemical responses during therapy at weeks 12, 24 and 48.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
peg-interferon alfa-2b
ribavirin
amantadine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who did not respond to treatment with standard interferon + ribavirin (HCV RNA+ by PCR in the last month of treatment)
* Compensated liver disease
* Neutrophil count over or equal to1000/mm3
* Platelet count over or equal to 100 giga/L
* Haemoglobin over or equal to 10g/dL
* Patients had to have undergone a post-treatment liver biopsy within a year, showing a METAVIR histological score over or equal to A1F1, without cirrhosis (fibrosis score below F4)
* ALT over N and HCV RNA+ at screening
Exclusion Criteria
* Any other cause of liver disease
* Active drug abuse, active alcohol consumption above 40g/day
* Organ grafts
* Presence of hepatocellular carcinoma
* Cardiovascular, metabolic, renal, haematological, neurological or psychiatric disease
* Patients with previous amantadine use
* Systemic immunosuppressive or antiviral treatment during the last 24 weeks and those with a history of interferon and/or ribavirin intolerance
18 Years
65 Years
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Schering-Plough
INDUSTRY
French National Agency for Research on AIDS and Viral Hepatitis
OTHER_GOV
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian Trepo, MD
Role: PRINCIPAL_INVESTIGATOR
Hépato-Gastroentérologie Hopital Hôtel-Dieu LYON
P. ADELEINE, MD
Role: STUDY_CHAIR
Laboratoire d'Informatique Médicale Lyon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service d'Hépato-Gastroentérologie Hopital Hotel Dieu
Lyon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANRSHC03 BITRI
Identifier Type: -
Identifier Source: org_study_id